Szablewski V, Bret C, Kassambara A, Devin J, Cartron G, Costes-Martineau V, Moreaux J. An epigenetic regulator-related score (EpiScore) predicts survival in patients with diffuse large B cell lymphoma and identifies patients who may benefit from epigenetic therapy. Oncotarget. 2018. Download the PDF
Summary of the Study
Diffuse large B-cell lymphoma (DLBCL) is a biologically and clinically heterogeneous cancer. In this study, researchers developed EpiScore, a gene expression–based risk score derived from the expression of three epigenetic regulators (DNMT3A, DOT1L, SETD8) to stratify patient prognosis and therapeutic potential.
EpiScore was validated in two independent DLBCL cohorts (n = 414 and n = 69)
It classified patients into low, intermediate, and high-risk groups
Outperformed established prognostic tools such as:
- IPI: International Prognostic Index
- ABC/GCB subtype
- GERS
- DNA repair score
Immunohistochemistry confirmed that DNMT3A overexpression was associated with worse survival
High-risk samples were enriched for an HDAC gene signature, suggesting vulnerability to epigenetic therapies
In this study, Alboukadel Kassambara contributed to the research, data analysis, and writing of the manuscript. He was specifically involved in the development and validation of the EpiScore, linking gene expression of epigenetic regulators to clinical outcomes in DLBCL.
Citation
Publication: In Oncotarget
Date: April 10, 2018
Type: Journal Article
PDF: Download the PDF
Scientific Contributions
Here are more scientific abstracts authored or co-authored by Alboukadel Kassambara. These contributions span computational biology, bioinformatics, biostatistics, machine learning, and multi-omics, with a focus on immuno-oncology and translational research.
